Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Glaxosmithkline Plc updates FY 2014 revenue guidance


Tuesday, 22 Apr 2014 02:01am EDT 

Glaxosmithkline Plc:Says proposed transaction with Novartis would increase GSK's fiscal 2014 revenues by 1.3 bln pounds to 26.9 bln pounds (on a 2013 pro forma basis) and fundamentally re-shape GSK's revenue base.Says these revenues would be split across Pharmaceuticals 62 pct., Consumer Healthcare 24 pct. and Vaccines 14 pct. 

Company Quote

18.084
-0.136 -0.75%
30 Jul 2014